Natural History, Reasons For, and Impact of Low/non-adherence to Medications for Osteoporosis in a Cohort of Community-dwelling Older Women Already Established on Medication: a 2-year Follow-up Study
Overview
Orthopedics
Authors
Affiliations
Unlabelled: Approximately 15 % of older women on oral medications for osteoporosis could be considered for alternatives including parenteral therapies. Collection of data on socio-demographic/clinical variables is unlikely to be helpful in predicting low/non-adherence. Alternative approaches are needed to identify individuals at risk of low/non-adherence.
Introduction: This study aims to identify individual patient reasons for stopping medications for osteoporosis, and to investigate whether this can be predicted from knowledge about socio-demographic/clinical data, or whether alternative approaches need to be used.
Methods: The Cohort for Skeletal Health in Bristol and Avon (COSHIBA) recruited 3200 older women from South West UK, of whom a proportion were on medications for osteoporosis at baseline. Information on self-reported adherence and reasons for low/non-adherence were collected at 6-monthly intervals over a 2-year period. Data was also collected on potential predictors of and impact of low/non-adherence.
Results: Two hundred thirty-three of 3200 (7.3 %) women were on medications for osteoporosis at baseline. Mean length of time on treatment prior to enrolment was 46 months. Of those on osteoporosis medications, 94.9 % were on bisphosphonates; 8.5 % reported low adherence and 21.6 % stopped their medication completely over the 2-year follow-up period. Length of time on medication at baseline did not influence rates of low/non-adherence. Reasons for low/non-adherence to bisphosphonates included side effects (53.9 %), practical reasons such as forgetting to take them (18.0 %) and beliefs about medications (20.5 %). No convincing predictors of low/non-adherence were identified.
Conclusions: Approximately 15 % of older women on oral medications for osteoporosis could be considered for alternatives including parenteral therapies. This has important implications for healthcare provision. Collection of data on socio-demographic/clinical variables is unlikely to be helpful in predicting low/non-adherence. Alternative approaches are needed to identify individuals at risk of low/non-adherence to osteoporosis medications.
Sturrock A, Grabrovaz M, Bullock L, Clark E, Finch T, Haining S BMJ Open. 2024; 14(11):e085323.
PMID: 39488418 PMC: 11535682. DOI: 10.1136/bmjopen-2024-085323.
Rafhi E, Al-Juhaishi M, Stupans I, Stevens J, Park J, Wang K Int J Clin Pharm. 2024; 46(4):811-830.
PMID: 38704779 PMC: 11286706. DOI: 10.1007/s11096-024-01727-9.
Seyok T, Collins J, Erikson S, Charles J, Earp B Hand (N Y). 2022; 19(2):256-262.
PMID: 36113071 PMC: 10953516. DOI: 10.1177/15589447221120851.
Paskins Z, Bullock L, Crawford-Manning F, Cottrell E, Fleming J, Leyland S BMJ Open. 2021; 11(8):e048811.
PMID: 34408051 PMC: 8375717. DOI: 10.1136/bmjopen-2021-048811.
Marozik P, Alekna V, Rudenko E, Tamulaitiene M, Rudenka A, Mastaviciute A PLoS One. 2019; 14(8):e0221511.
PMID: 31437227 PMC: 6705789. DOI: 10.1371/journal.pone.0221511.